Today, the U.S. Food and Drug Administration approved Wegovy (semaglutide) injection (2.4 mg once weekly) for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), for use in addition to a reduced calorie diet and increased physical activity.
FDA approves new drug treatment for chronic weight management, first since 2014
June 5, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022